Financial News
Latest News about BHVN
Recent news which mentions BHVN
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
May 16, 2022
From Benzinga
3 Dirt-Cheap Stocks You Can Buy Right Now
May 14, 2022
From Motley Fool
From Benzinga
103 Biggest Movers From Yesterday
May 11, 2022
From Benzinga
From InvestorPlace
Why Biohaven Pharmaceutical Stock Soared Today
May 10, 2022
From Motley Fool
From Benzinga
From Motley Fool
From Benzinga
From Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
May 10, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From MarketWatch
From Benzinga
European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine
April 27, 2022
From Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
From Benzinga
From Benzinga
Biohaven Pharmaceutical's Return On Capital Employed Insights
February 28, 2022
Tickers
BHVN
From Benzinga
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals
February 25, 2022
From Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
February 25, 2022
From Benzinga
Earnings Scheduled For February 25, 2022
February 25, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints
February 14, 2022
From Benzinga
What to Expect From Biogen's $2.3 Billion Shopping Spree
February 12, 2022
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.